Programme 2017-11-29T09:04:14+00:00



07:30                       Registration opens

10:00 – 10:15          Welcome and Introduction, J Barker (London, UK), C Griffiths (Manchester, UK)

Scientific Session 1

Chairs: H. Bachelez (France), E. Prens (The Netherlands)

10:15 – 10:25          FC01 Psoriasis and risk of malignant lymphoma: a population-based cohort study
M. Kamstrup, L. Skov, C. Zachariae, J. Thyssen and A. Egeberg

10:25 – 10:35          FC02 Developing a therapeutic range and predicting response to biologics in patients with psoriasis: a multicentre prospective observational                                     cohort study
T. Tsakok and the PSORT Consortium

10:35 – 10:45         FC03 The differential production of interleukin (IL)-26 vs. IL-17 by T helper 17 cells contributes to the development of different forms of psoriasis
A. Fries, J. Di Domizio, O. Demaria and M. Gilliet

10:45 – 11:15          Invited speaker B. Andersson (Solna, Sweden), The human skin microbiome and implications for disease

11:15 – 11:45          Coffee break

11:45 – 11:55          FC04 Psoriasis-associated late cornified envelope) proteins have antibacterial activity
H. Niehues, L. Tsoi, D. van der Krieken, P. Jansen, M. Oortveld, D. Rodijk-Olthuis, I. van Vlijmen-Willems, W. Hendriks, R. Helder, J. Bouwstra, R.                                   Mesman, L. van Niftrik, E. van den Bogaard, P. Stuart, R. Nair, J. Elder, P. Zeeuwen and J. Schalkwijk

11:55 – 12:05          FC05 Environmental antigens may trigger HLA-C*06:02-mediated autoimmunity in psoriasis
Y. Arakawa, A. Arakawa, S. Vural, A. Galinski, S. Vollmer and J. Prinz

12:05 – 12:15          FC06 Analysis of psoriasis host-microbiome interactions using a universal transcriptomic approach
T. Furnholm, M. Foo, J. Henderson, K. Shedden and A. Johnston

12:15 – 12:45          Invited speaker V. Kuchroo (Cambridge, USA), Transcriptional networks and factors involved in IL17 differentiation

12:45 – 13:45          Lunch and poster viewing

Scientific Session 2

Chairs: R. Warren (UK), C. Smith (UK)

13:45 – 13:55          FC07 Genetic variation contributes to response to biologics: initial findings of the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) consortium
N. Dand 

13:55 – 14:05          FC08 Comparative Evaluation of Cellular and Molecular Changes Associated with Response to Selective IL-23 Blockade vs Dual IL-12/23 Blockade in Psoriasis Skin
K. Li, K. Campbell, S. Garcet, C. Brodmerkel1 and J. Krueger

14:05 – 14:15          FC08 Functional immunophenotyping analysis reveals adalimumab-induced impairment of TNF signalling in lymphoid cells in psoriasis
R.A. Ejarque 

14:15 – 15:00          Keynote lecture, J. Savill (Edinburgh, UK) The importance of academic-industrial collaboration to the future of medical research

15:00 – 15:45          Tea break

15:45 – 16:15          Sponsored lecture 1 – Lilly
Targeting IL-17: Findings From Recent Clinical Trials
A. Blauvelt (Portland, USA)

16:20 – 16:50          Sponsored lecture 2 – Almirall
The epidemiology and interrelation of psoriasis and other IL-23 related diseases
A. Kimball (Boston, USA)

17:00 – 19:30          Welcome Reception, The Queen Elizabeth II Conference Centre


Scientific Session 3

Chairs: J. Elder (USA), M. Gilliet (Switzerland)

08:00 – 08:30            Sponsored lecture 3 – Leo
Pro-inflammatory redundancy in the IL-17 pathway – the role of the individual IL-17 cytokine family members in psoriasis
J. Krueger (New York, USA)

08:35 – 09:05            Sponsored lecture 4 – Janssen
IL-23 inhibition as a strategy to treat immune-mediated inflammatory diseases
J. Prinz (Munich, Germany) & S. Danese (Milan, Italy)

09:05 – 09:15           FC10 The genetic basis for most patients with pustular skin disease remains elusive
U. Hüffmeier, S. Löhr, P. Schulz, A. Körber, J.C. Prinz, K. Schäkel, S. Philipp, K. Reich, H. Ständer, A. Jacobi, K. Kingo, S. Koks, S. Gerdes, T. Schill, K.G. Griewank, S. Frey, K. Steinz, S. Uebe, M. Sticherling, H. Sticht, P. Gkogkolou, V. Oji, D. Wilsmann-Theis and R. Mössner

09:15 – 09:25           FC11 ADAM17 and TIMP3 are psoriasis-relevant check-points controlling Th17-programming by inflammatory dermal dendritic cells
A. Kunze, A. Rendon, S. Oehrl, G. Murphy, A. Enk and K. Schäkel 

09:25 – 09:35           FC12 Genotype and phenotype analyses revealed novel susceptibility genes and new clinical classification for psoriasis.
B.-J. Feng, S. McCarthy, H. Li, K. Praveen, J. Walsh, J. Hawkes, M. Milliken, D. Goldgar, J. Reid, J. Overton, F. Dewey, C. Gonzaga-Jauregui, S. Guthery, K. Callis Duffin and G. Krueger

09:35 – 09:45           FC13 Advances in genomic studies of psoriasis in China
X. Zhang

09:45 – 10:15           Invited speaker, A. Franke (Kiel, Germany), Cross-disease genetic analyses of chronic inflammatory diseases

10:15 – 10:45           Coffee break

Chairs: L. Iversen (Denmark), J. Krueger (USA)

10:45 – 10:55           FC14 iRhom2 – a mechanistic hub in keratinocyte hyperproliferation and psoriasis?
M. Brooke, T. Maruthappu, A. Chikh and D. Kelsell

10:55 – 11:05           FC15 Identifying chromatin interactions between psoriasis-associated variants and target genes using Capture Hi-C
H. Ray-Jones, A. McGovern, P. Martin, K. Duffus, S. Eyre and R.B. Warren

11:05 – 11:15           FC16 The psoriasis-associated Act1(D10N) variant reduces responses to IL17 but enhances Th17 responses to polyclonal activation
S. Lambert, C. Hambro, A. Johnston, R. Nair and J. Elder 

11:15 – 11:25           FC17 ERAP1 risk variants in psoriasis vulgaris affect autoantigen presentation
A. Arakawa, S. Vollmer, E. Reeves, E. James and J.C. Prinz

11:25 – 11:55            Invited speaker, T. Lappalainen (New York, USA), From genome wide association to functional relevance

11:55 – 12:05           FC18 TNF blockade induces a dysregulated type I IFN response without autoimmunity in paradoxical psoriasis
C. Conrad, J. Di Domizio, A. Mylonas, O. Demaria, C. Belkhodja, A. Navarini, A.-K. Lapointe, L. French, M. Vernez and M. Gillliet

12:05 – 12:15           FC19 Activation of resident T cells in resolved psoriasis reveals tissue responses that stratify clinical outcome
I.G. Sérézal, C. Classon, S. Nylén, N.X. Landén, E. Martini, S. Cheuk and L. Eidsmo

12:15 – 13:15           Lunch and poster viewing

Scientific Session 4

Chairs: A. Kimball (USA), D. Burden (UK)

13:15 – 13:25           FC20 Longitudinal follow-up of arterial structure and function in patients with severe psoriasis treated by anti-IL12/IL-23 compared to TNF inhibitors
M. Viguier, H. Khettab, I. Hamdidouche, P. Boutouyrie and H. Bachelez

13:25 – 13:35           FC21 Real-World Experience With Apremilast in Psoriasis Patients: Interim Analysis of 104 Patients From the APPRECIATE Study
E. Kleyn, M. Radtke, C. Bundy, K. Eyerich, M. Ståhle, M. Cordey, V. Koscielny, C.E.M. Griffiths and M. Augustin

13:35 – 13:45           FC22 Topical MTX-GNPs reduce IMQ-induced inflammation in mice
A. Özcan, D. Bunton, G. Macluskie, M. Duric, J. Barry and A. Kolios

13:45 – 13:55           FC23 Efficacy and safety of secukinumab in anti-TNFα failure patients from the UK and Republic of Ireland: Results of the SIGNATURE study
R.B. Warren, J. Barker, D. Burden, A. Finlay, C. Hatchard, P. Jeffery, R. Williams and C.E.M. Griffiths

13:55 – 14:25         Invited speaker, A. Gils (Leuven, Belgium), Why biologics fail

14:25 – 15:10         Tea break

Scientific Session 5

Chairs: P. Van de Kerkhof (The Netherlands), H. Bachelez (France)

15:10 – 15:20          FC24 The genetic analysis of a large pustular psoriasis resource highlights differential effects for IL36RN and AP1S3 mutations.
S. Twelves, K. Farkas, S.E. Choon, D. Burden, C.E.M. Griffiths, A. Irvine, E. Tan, M. Szell, Z. Bata-Csorgo, C. Smith, F. Capon and J. Barker

15:20 – 15:30          FC25 Transcriptomic profiling of IL-36A, IL-36B and IL-36G cytokine responses in keratinocytes demonstrates high degree of overlap and dependency on Myd88 and NFkB signaling.
W. Swindell, M. Sarkar, M. Beamer, X. Xing, M. Kahlenberg, N. Ward, J. Voorhees,L. Tsoi, Y. Liang and J. Gudjonsson 

15:30 – 16:00          Invited Lecture, J. Towne (San Diego, USA), Biology and pathology of IL-36

16:05 – 16:35          Sponsored lecture 5 – Abbvie
The evolution of T cell targeted therapy in psoriasis
J. Barker (London, UK)

16:40 – 17:10          Sponsored lecture 6 – UCB
Re-evaluating the role of IL-17F in immune-mediated chronic inflammation:
dual neutralisation of both IL-17A and IL-17F as a novel targeting approach in psoriatic diseases
S. Shaw (Slough, UK)

19:30 – 23:00          Congress Dinner, The Natural History Museum


Scientific Session 6

Chairs: A. Menter (USA), J. Prinz (Germany)

08:40 – 09:10           Sponsored lecture 7 – Novartis
Disease modification, from bedside to bench
L. Iversen (Aarhus, Denmark) & L. Eidsmo (Stockholm, Sweden)

09:15 – 09:45           Sponsored lecture 8 – Celgene
The complex management of patients with psoriasis and comorbidities: the role of therapy choice
P. Gisondi (Verona, Italy)

09:45 – 09:55           FC26 Effectiveness, drug survival and safety of fumaric acid esters for moderate to severe psoriasis in routine care: Results from the German Psoriasis Registry PsoBest
M. Augustin, U. Mrowietz, M.A. Radtke, D. Thaci, K. Ralph, A. Körber and K. Reich

09:55 – 10:05           FC27 The lymphatic system plays an important role in the migration of pathogenic
T-cells towards synovial joints and entheses in psoriasis.
D. Verhaegh, E. Prens, A.M.C. Mus, P.S. Asmawidjaja, N. Davelaar, A. Hofman, J.-B. Jaquet, J.M.W. Hazes, M.R. Kok, E. Lubberts and R.J. Bisoendial

10:05 – 10:15           FC28 Systemic inflammation and evidence of a cardio-splenic axis in psoriasis patients
K.F. Hjuler, L.C. Gormsen, M.H. Vendelbo, A. Egeberg, J. Nielsen and L. Iversen

10:15 – 10:45           Invited Lecture, U. Mrowietz (Kiel, Germany), Challenging conventional classification dogma: towards a new clinical taxonomy of psoriasis

10:45 – 11:15           Coffee Break

Chairs: J. Barker (UK), C. Griffiths (UK)

11:15 – 11:25           FC29 Efficacy and Safety of Risankizumab, an IL-23 Inhibitor, in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: 16-Week Results from the Phase 3 IMMhance Trial
A. Blauvelt, K.A. Papp, M. Gooderham, R.G. Langley, C. Leonardi, J.-P. Lacour, S. Philipp, S. Tyring, M. Bukhalo, J.J. Wu, J. Bagel, E.H. Frankel, D. Pariser, M. Flack, J. Scherer, Z. Geng, Y. Gu, A. Camez and E.H.Z. Thompson

11:25 – 11:35           FC30 Quality of care and use of systemic drugs for psoriasis in the past 12 years – results from a series of nationwide health care studies in Germany
M. Radtke, M. Augustin and K. Reich

11:35 – 12:05          Invited Lecture, J. Scannell (Edinburgh, UK), The price and value of biologic drugs

12:05 – 12:15          FC31 Efficacy and Safety of mirikizumab1 (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: Results from a Phase 2 study
K. Reich, R. Bissonnette, A. Menter, P. Klekotka, D. Patel, J. Li, J. Tuttle and K. Papp

12:15 – 12:25          FC32 Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: an overview of 3 randomized controlled trials
A. Blauvelt, K. Reich, M. Lebwohl, D. Burge, C. Arendt, L. Peterson, J. Drew, R. Rolleri and A. Gottlieb

12:25 – 12:35          FC33 Switching or restarting of TNF-α inhibitors after interruption under daily life conditions: Efficacy report from the Austrian Psoriasis Registry (PsoRA)
P. Wolf, W. Weger, L. Richter, A. Mlynek, P. Sator, W. Saxinger, G. Ratzinger, C. Kölli, C. Painsi, C. Bangert, R. Tatarski, M. Schütz-Bergmayr, P. Ponholzer, F. Trautinger, R. Strohal, R. Müllegger, M. Inzinger, R. Lichem, W. Salmhofer and F. Quehenberger

12:35 – 13:20          Keynote lecture, L. Hood (Seattle, USA), P4 Medicine and Systems Medicine

13:20                       Presentation of poster prizes and close of Congress, J Barker (London, UK), C Griffiths (Manchester, UK)

Official Language

All congress sessions will be in English.